What is Onivyde and What Does it Treat?
Onivyde is a brand name for irinotecan liposome, a chemotherapy drug used to treat pancreatic cancer. Specifically, it is indicated for patients with metastatic adenocarcinoma of the pancreas whose disease has progressed following gemcitabine-based therapy [1]. Onivyde is administered intravenously [1].
How Effective is Onivyde in Clinical Trials?
In a Phase 3 clinical trial that led to its approval, Onivyde was studied in combination with fluorouracil and leucovorin. This regimen was compared to fluorouracil and leucovorin alone in patients with previously treated metastatic pancreatic cancer. The combination therapy demonstrated a statistically significant improvement in overall survival compared to the control group [1]. The median overall survival for patients receiving Onivyde plus fluorouracil and leucovorin was 6.1 months, versus 4.2 months for those receiving fluorouracil and leucovorin alone [1].
What are the Potential Side Effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis (mouth sores), and pyrexia (fever) [1]. Severe side effects can include severe diarrhea, neutropenia (low white blood cell count), febrile neutropenia, and hypersensitivity reactions [1]. Diarrhea is a particularly important side effect to manage, as severe or prolonged diarrhea can lead to dehydration, electrolyte imbalance, and kidney failure [1].
When Does Onivyde's Patent Protection End?
Information regarding specific patent expiry dates for Onivyde is not publicly available in the provided context. Drug patent information, including expiry dates and any associated litigation, can be complex and is often tracked by specialized databases [2].
What are the Next Steps for Pancreatic Cancer Treatment?
Research continues to explore new and improved treatment strategies for pancreatic cancer. This includes investigating novel drug combinations, targeted therapies, and immunotherapies. The development of new treatments aims to improve patient outcomes, including survival rates and quality of life, for this challenging disease [3].